Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis (Q35842626)

10 August 2017

1 reference

title

Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis (English)

1 reference

10 August 2017

1 reference

1 reference

Roy Fleischmann

1

1 reference

10 August 2017

Richard Stern

series ordinal

2

1 reference

10 August 2017

Imran Iqbal

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

1333-1344

1 reference

10 August 2017

8

1 reference

Cytokine pathways and joint inflammation in rheumatoid arthritis

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Adhesion molecules: a rheumatologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Bone changes in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Potential biologic agents for treating rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Pharmacokinetics of anakinra in subjects with different levels of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Predictors of infection in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Infections and anti–tumor necrosis factor α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

Rheumatoid arthritis and cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.8.1333

10.1517/14712598.4.8.1333

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference